Cellular Determinants of Fibrin Structure and Stability
纤维蛋白结构和稳定性的细胞决定因素
基本信息
- 批准号:7735611
- 负责人:
- 金额:$ 32.95万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-09-10 至 2014-04-30
- 项目状态:已结题
- 来源:
- 关键词:AffectAnticoagulantsBloodBlood ClotBlood Coagulation FactorBlood VesselsBlood coagulationBlood flowCause of DeathCell surfaceCellsCoagulation ProcessDataDiffusionDiseaseDistalEmbolismEndothelial CellsFiberFibrinFibrinolysisFibroblastsGenerationsGrowthHemorrhageHemostatic AgentsHumanIn SituInfectionInjuryIntegrinsInternetLaser Scanning Confocal MicroscopyLocationMeasuresMechanicsMicroscopyMicrospheresMorphologyOutcomePermeabilityPlasmaPredispositionProductionProteinsReceptor CellResearchResistanceRiskRisk FactorsRoleSiteSmooth Muscle MyocytesStructureSupporting CellSurfaceTechniquesTechnologyTestingThrombinThrombomodulinThromboplastinThrombosisThrombusTransmission Electron MicroscopyWestern WorldWound Healingcytokinedensitydisabilityin vivonovelphysical propertypreventpublic health relevancereceptorreceptor expressionresearch studythree dimensional structure
项目摘要
DESCRIPTION (provided by applicant): Following injury, tissue factor (TF)-bearing cells are exposed to the blood, triggering blood clot formation. Blood clots are stabilized by a web-like network of fibrin, which protects the clot from the rigors of flowing blood. Fibrin also has immunological functions during infection and contributes to wound healing. Studies have shown that abnormalities in the formation or quality (structure and/or stability) of the fibrin network are an established, independent risk factor for abnormal blood clots (thrombosis and/or bleeding). We and others have shown that different cells determine fibrin quality via their procoagulant activity and receptor expression. Interestingly, both cellular procoagulant activity and receptors produce fibrin that is denser and more stable near the cell than further away from the cell surface. We hypothesize that the spatial location of thrombin generation influences clot structure and stability. We will use laser scanning confocal microscopy to characterize activities that regulate fibrin clot structure proximal and distal to the site of clotting initiation. We will specifically investigate the roles of cell stimulation, cellular and circulating tissue factor, soluble clotting factors, and cell receptors in determining clot structure. We will use passive and magnetically-driven microbead techniques and microscopy to examine how vascular cells modulate fibrin network permeability, mechanical strength and resistance to fibrinolysis. Finally, we will use transmission electron microscopy to compare fibrin structure in clots formed under different shear rates on freshly-excised human vessels. We anticipate our data will show how different hemostatic and prothrombotic mechanisms contribute to clot structure and stability in static and low shear conditions. These mechanisms may be specific targets for preventing intravascular thrombosis and/or embolism. PUBLIC HEALTH RELEVANCE: Inappropriate blood clot formation (thrombosis) is the leading cause of death and disability in the Western world. Understanding the mechanisms leading to thrombosis is critical in order to develop approaches for preventing this devastating disease.
描述(由申请人提供):损伤后,携带组织因子(TF)的细胞暴露于血液中,引发血凝块形成。血凝块是由纤维蛋白组成的网状网络稳定的,它保护血凝块不受血液流动的冲击。纤维蛋白在感染过程中也具有免疫功能,有助于伤口愈合。研究表明,纤维蛋白网络的形成或质量(结构和/或稳定性)异常是异常血块(血栓形成和/或出血)的一个确定的、独立的危险因素。我们和其他人已经表明,不同的细胞通过促凝活性和受体表达来决定纤维蛋白的质量。有趣的是,细胞促凝活性和受体产生的纤维蛋白在细胞附近比远离细胞表面更密集、更稳定。我们假设凝血酶生成的空间位置影响凝块结构和稳定性。我们将使用激光扫描共聚焦显微镜来表征调节凝血起始部位近端和远端纤维蛋白凝块结构的活动。我们将特别研究细胞刺激、细胞和循环组织因子、可溶性凝血因子和细胞受体在决定凝块结构中的作用。我们将使用被动和磁驱动的微珠技术和显微镜来研究血管细胞如何调节纤维蛋白网络的渗透性、机械强度和纤维蛋白溶解的抵抗力。最后,我们将使用透射电子显微镜来比较在不同剪切速率下在新鲜切除的人血管上形成的血块中的纤维蛋白结构。我们预计我们的数据将显示在静态和低剪切条件下,不同的止血和血栓形成机制如何促进凝块结构和稳定性。这些机制可能是预防血管内血栓形成和/或栓塞的特定靶点。公共卫生相关性:在西方世界,不适当的血凝块形成(血栓)是导致死亡和残疾的主要原因。了解导致血栓形成的机制对于开发预防这种毁灭性疾病的方法至关重要。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Alisa S. Wolberg其他文献
436: Effect of tranexamic acid dose on clot lysis: implications for preventing postpartum hemorrhage
- DOI:
10.1016/j.ajog.2019.11.452 - 发表时间:
2020-01-01 - 期刊:
- 影响因子:
- 作者:
Homa K. Ahmadzia;Naomi L. Luban;Alexandra North;Jeffrey Berger;Andra H. James;Alisa S. Wolberg;John van den Anker - 通讯作者:
John van den Anker
Pancreatic Ductal Adenocarcinoma Causes Bleeding Phenotype in Mice Associated with Loss of Procoagulant Activity and Increased Thrombomodulin Sensitivity
- DOI:
10.1182/blood-2022-169582 - 发表时间:
2022-11-15 - 期刊:
- 影响因子:
- 作者:
Michelle M. Luo;Keely G. Davey;Yohei Hisada;Yi Yang;Lori A. Holle;Ananya Dutta;Brian C. Cooley;Nigel Mackman;Matthew J. Flick;Alisa S. Wolberg - 通讯作者:
Alisa S. Wolberg
Thrombocytopenia in a Mouse Model of Pancreatic Cancer
- DOI:
10.1182/blood-2022-169771 - 发表时间:
2022-11-15 - 期刊:
- 影响因子:
- 作者:
Michelle M. Luo;Yaqiu Sang;Maria N. Barrachina;Andrew P. Stone;Keely G. Davey;Yi Yang;Lori A. Holle;Tomohiro Kawano;Nigel Mackman;Matthew J. Flick;Kellie R. Machlus;Alisa S. Wolberg - 通讯作者:
Alisa S. Wolberg
Agnostic identification of plasma biomarkers for postpartum hemorrhage risk
产后出血风险血浆生物标志物的不可知论鉴定 (注:这里agnostic 比较生僻,“不可知论”是其常见意思,结合语境可能有更准确含义,需看更多背景信息来精准判断。一般医学语境里agnostic有“诊断的”意思,这里翻译为“诊断性鉴定”或许更合适些 :产后出血风险血浆生物标志物的诊断性鉴定 )
- DOI:
10.1016/j.ajog.2024.04.050 - 发表时间:
2025-02-01 - 期刊:
- 影响因子:8.400
- 作者:
Stéphanie E. Reitsma;Julia R. Barsoum;Kirk C. Hansen;Alexa M. Sassin;Monika Dzieciatkowska;Andra H. James;Kjersti M. Aagaard;Homa K. Ahmadzia;Alisa S. Wolberg - 通讯作者:
Alisa S. Wolberg
Hypofibrinogenemia with preserved hemostasis and protection from thrombosis in mice with an emFga/em truncation mutation
具有保留止血功能和预防血栓形成的 emFga/em 截短突变小鼠的低纤维蛋白原血症
- DOI:
10.1182/blood.2021012537 - 发表时间:
2022-03-03 - 期刊:
- 影响因子:23.100
- 作者:
Woosuk S. Hur;David S. Paul;Emma G. Bouck;Oscar A. Negrón;Jean-Marie Mwiza;Lauren G. Poole;Holly M. Cline-Fedewa;Emily G. Clark;Lih Jiin Juang;Jerry Leung;Christian J. Kastrup;Tatiana P. Ugarova;Alisa S. Wolberg;James P. Luyendyk;Wolfgang Bergmeier;Matthew J. Flick - 通讯作者:
Matthew J. Flick
Alisa S. Wolberg的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Alisa S. Wolberg', 18)}}的其他基金
Enhancement Training for the Next Generation of Translational Ph.D. Scientists
下一代转化博士的强化培训
- 批准号:
10413926 - 财政年份:2018
- 资助金额:
$ 32.95万 - 项目类别:
Enhancement Training for the Next Generation of Translational Ph.D. Scientists
下一代转化博士的强化培训
- 批准号:
10198943 - 财政年份:2018
- 资助金额:
$ 32.95万 - 项目类别:
Fibrinogen and Factor XIII in Venous Thrombosis
静脉血栓形成中的纤维蛋白原和因子 XIII
- 批准号:
9205251 - 财政年份:2016
- 资助金额:
$ 32.95万 - 项目类别:
Fibrinogen and Factor XIII in Venous Thromboembolism
静脉血栓栓塞中的纤维蛋白原和因子 XIII
- 批准号:
10205143 - 财政年份:2016
- 资助金额:
$ 32.95万 - 项目类别:
Fibrinogen and Factor XIII in Venous Thromboembolism
静脉血栓栓塞中的纤维蛋白原和因子 XIII
- 批准号:
10649632 - 财政年份:2016
- 资助金额:
$ 32.95万 - 项目类别:
Fibrinogen and Factor XIII in Venous Thromboembolism
静脉血栓栓塞中的纤维蛋白原和因子 XIII
- 批准号:
10463593 - 财政年份:2016
- 资助金额:
$ 32.95万 - 项目类别:
Fibrinogen and Factor XIII in Venous Thromboembolism
静脉血栓栓塞中的纤维蛋白原和因子 XIII
- 批准号:
10065898 - 财政年份:2016
- 资助金额:
$ 32.95万 - 项目类别:
Determinants of Thrombus Structure and Stability
血栓结构和稳定性的决定因素
- 批准号:
8903582 - 财政年份:2014
- 资助金额:
$ 32.95万 - 项目类别:
Cellular Determinants of Fibrin Structure and Stability
纤维蛋白结构和稳定性的细胞决定因素
- 批准号:
8073476 - 财政年份:2009
- 资助金额:
$ 32.95万 - 项目类别:
Cellular Determinants of Fibrin Structure and Stability
纤维蛋白结构和稳定性的细胞决定因素
- 批准号:
7930677 - 财政年份:2009
- 资助金额:
$ 32.95万 - 项目类别:
相似海外基金
EPIphANy (Evaluation of Pharmacological Interactions with Anticoagulants in caNcer patients) program - prostate cancer cohort
EPIPHANy(癌症患者抗凝药理相互作用的评估)计划 - 前列腺癌队列
- 批准号:
479295 - 财政年份:2023
- 资助金额:
$ 32.95万 - 项目类别:
Operating Grants
Inhibitors of Human Factor XIIIa as New Anticoagulants
人类因子 XIIIa 抑制剂作为新型抗凝剂
- 批准号:
10629057 - 财政年份:2023
- 资助金额:
$ 32.95万 - 项目类别:
Establishment of comprehensive monitoring of direct oral anticoagulants (DOACs) for clinical application
建立临床应用直接口服抗凝剂(DOAC)综合监测体系
- 批准号:
23K06906 - 财政年份:2023
- 资助金额:
$ 32.95万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Interactions of Enzyme-Inducing Antiepileptic Drugs with Direct-Acting Oral Anticoagulants: Risk of Thromboembolic Events
酶诱导抗癫痫药物与直接作用口服抗凝剂的相互作用:血栓栓塞事件的风险
- 批准号:
10605482 - 财政年份:2023
- 资助金额:
$ 32.95万 - 项目类别:
The Comparative Effectiveness and Safety of Oral Anticoagulants in Patients with Cirrhosis and Atrial Fibrillation
口服抗凝药对肝硬化合并心房颤动患者的有效性和安全性比较
- 批准号:
10559071 - 财政年份:2023
- 资助金额:
$ 32.95万 - 项目类别:
Search for indicators of blood levels of directly inhibitory oral anticoagulants in coagulation tests using artificial intelligence
使用人工智能在凝血测试中搜索直接抑制性口服抗凝剂的血液水平指标
- 批准号:
22K07388 - 财政年份:2022
- 资助金额:
$ 32.95万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Bleeding on Direct Oral Anticoagulants: Identification of Genetic Risk Factors and a Polygenic Predictive Score in Patients with Atrial Fibrillation
直接口服抗凝剂导致的出血:房颤患者遗传风险因素的鉴定和多基因预测评分
- 批准号:
10536789 - 财政年份:2022
- 资助金额:
$ 32.95万 - 项目类别:
Study on proper use of oral anticoagulants combined with 5-fluorouracil
口服抗凝药联合5-氟尿嘧啶正确使用研究
- 批准号:
22K06743 - 财政年份:2022
- 资助金额:
$ 32.95万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Benchmarking a point-of-care test kit for detection of direct-oral anticoagulants
用于检测直接口服抗凝剂的即时检测试剂盒的基准测试
- 批准号:
461790 - 财政年份:2022
- 资助金额:
$ 32.95万 - 项目类别:
Operating Grants
Direct oral anticoagulants and the risk of colorectal and pancreatic cancers: a population-based cohort study.
直接口服抗凝剂与结直肠癌和胰腺癌的风险:一项基于人群的队列研究。
- 批准号:
474475 - 财政年份:2022
- 资助金额:
$ 32.95万 - 项目类别:
Studentship Programs